Innate Pharma Shifts PACIFIC-9 Trial Readout to H1 2027
AstraZeneca now expects high-level data from the Phase 3 PACIFIC-9 trial in H1 2027, revised from H2 2026. Enrollment is complete, and the study is event-driven.
AstraZeneca now expects high-level data from the Phase 3 PACIFIC-9 trial in H1 2027, revised from H2 2026. Enrollment is complete, and the study is event-driven.